User login
Key clinical point: The efficacy and safety profile of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) in routine clinical practice is similar to that reported in the phase 3 IMbrave150 study.
Major finding: After a median follow-up of 10.0 months, the median overall survival was 15.7 months (95% CI 14.50-not estimated) and the progression-free survival was 6.9 months (95% CI 6.10-8.30). Among response-evaluable patients (n = 273), 30.8% achieved an objective response. Grade 3/4 treatment-related adverse events occurred in 23.6% of patients.
Study details: This multicenter prospective observational study, AB-Real, included 296 patients who received first-line atezolizumab plus bevacizumab for unresectable HCC.
Disclosures: This study received no specific funding. Some authors declared serving as consultants, advisors, or receiving lecture fees, advisory board honoraria, research grants, or travel or accommodation expenses from various sources.
Source: Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-213 (Sep 20). Doi: 10.1016/j.ejca.2022.08.024
Key clinical point: The efficacy and safety profile of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) in routine clinical practice is similar to that reported in the phase 3 IMbrave150 study.
Major finding: After a median follow-up of 10.0 months, the median overall survival was 15.7 months (95% CI 14.50-not estimated) and the progression-free survival was 6.9 months (95% CI 6.10-8.30). Among response-evaluable patients (n = 273), 30.8% achieved an objective response. Grade 3/4 treatment-related adverse events occurred in 23.6% of patients.
Study details: This multicenter prospective observational study, AB-Real, included 296 patients who received first-line atezolizumab plus bevacizumab for unresectable HCC.
Disclosures: This study received no specific funding. Some authors declared serving as consultants, advisors, or receiving lecture fees, advisory board honoraria, research grants, or travel or accommodation expenses from various sources.
Source: Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-213 (Sep 20). Doi: 10.1016/j.ejca.2022.08.024
Key clinical point: The efficacy and safety profile of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (HCC) in routine clinical practice is similar to that reported in the phase 3 IMbrave150 study.
Major finding: After a median follow-up of 10.0 months, the median overall survival was 15.7 months (95% CI 14.50-not estimated) and the progression-free survival was 6.9 months (95% CI 6.10-8.30). Among response-evaluable patients (n = 273), 30.8% achieved an objective response. Grade 3/4 treatment-related adverse events occurred in 23.6% of patients.
Study details: This multicenter prospective observational study, AB-Real, included 296 patients who received first-line atezolizumab plus bevacizumab for unresectable HCC.
Disclosures: This study received no specific funding. Some authors declared serving as consultants, advisors, or receiving lecture fees, advisory board honoraria, research grants, or travel or accommodation expenses from various sources.
Source: Fulgenzi CAM et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. 2022;175:204-213 (Sep 20). Doi: 10.1016/j.ejca.2022.08.024